Aramis Biosciences has completed enrollment for its phase 2 proof-of-concept clinical trial analyzing A197 for the treatment of dry eye disease.
Tell me more about A197.
A197 is a novel, first-in-class, topical immunomodulatory agent designed to target the immunopathogenesis of DED.
What is the trial evaluating?
The phase two study (NCT05238597) is evaluating the safety, tolerability, and efficacy of two doses of A197 in 207 participants with DED. Its primary endpoint is a measurement of change from baseline in corneal fluorescein staining, while the secondary endpoint is evaluating eye dryness symptoms via the visual analog scale. (via)
Where is it being conducted?
Across 24 centers in the U.S.
When can we expect results?
Topline data is expected by the end of Q1 2023.